These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 33203663)

  • 1. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
    Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of
    Gao Y; Luo Q; Sun Z; Gao H; Yu Y; Sun Y; Ma X; Han C; Shi J; Wang F
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36858461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
    Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
    Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
    [No Abstract]   [Full Text] [Related]  

  • 4. Noninvasive Imaging of Tumor PD-L1 Expression Using [
    Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J
    Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel
    Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B
    Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Phase I Study of a
    Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J
    J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
    Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N
    Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-rater and intra-rater agreement of [
    Hughes DJ; Chand G; Johnson J; Bailey D; Adamson K; Goh V; Cook GJR
    EJNMMI Res; 2023 May; 13(1):51. PubMed ID: 37256434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel small
    Liang Z; Hu X; Hu H; Wang P; Cai J
    Front Oncol; 2022; 12():1017737. PubMed ID: 36387113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter- and intraobserver agreement of the quantitative assessment of [
    Hughes DJ; Chand G; Goh V; Cook GJR
    EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy between
    Zhu YC; Elsheikha HM; Wang JH; Fang S; He JJ; Zhu XQ; Chen J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
    Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development and characterisation of
    Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM
    Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Ferro-Flores G; Ocampo-García B; Cruz-Nova P; Luna-Gutiérrez M; Bravo-Villegas G; Azorín-Vega E; Jiménez-Mancilla N; Michel-Sánchez E; García-Pérez O; Lara-Almazán N; Santos-Cuevas C
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.